Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer
Abstract We here investigate the expression of the mitochondrial carrier homolog 2 (MTCH2) and its potential function in castration-resistant prostate cancer (CRPC). Bioinformatic analyses reveal that MTCH2 overexpression is associated with critical clinical parameters of prostate cancer. Single-cel...
Saved in:
Main Authors: | Yankui Liu, Anjie Chen, Yufan Wu, Jiang Ni, Rong Wang, Yong Mao, Ning Sun, Yuanyuan Mi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-02-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-025-07406-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
by: Goran Bencina, et al.
Published: (2023-06-01) -
Real-World Treatment Patterns in Men with Castration- Resistant Prostate Cancer Receiving Docetaxel
by: Keith L. Davis, et al.
Published: (2015-01-01) -
ANO7 expression in the prostate modulates mitochondrial function and lipid metabolism
by: Christoffer Löf, et al.
Published: (2025-02-01) -
A manifesting female carrier of Duchenne muscular dystrophy: importance of genetics for the dystrophinopathies
by: Zhi Xuan Quak, et al.
Published: (2023-01-01) -
Mitochondrial DNA leakage: underlying mechanisms and therapeutic implications in neurological disorders
by: Guangming Zhang, et al.
Published: (2025-02-01)